0000000000815541

AUTHOR

Kris Kowdley

showing 2 related works from this author

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A…

2013

International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavi…

Maleviruses[SDV]Life Sciences [q-bio]Hepacivirusmedicine.disease_causeGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawErythropoiesisIncidenceGastroenterologyDisease Managementvirus diseasesAnemiaMiddle AgedRecombinant Proteins3. Good healthTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAlgorithmsmedicine.drugmedicine.medical_specialtyGenotypeProlineSide effectAnemiaHepatitis C virusInterferon alpha-2Antiviral Agents03 medical and health sciencesInternal medicineBoceprevirRibavirinmedicineHumansErythropoietinDAADose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicbiochemical phenomena metabolism and nutritionmedicine.diseasedigestive system diseasesSide EffectLogistic ModelschemistryErythropoietinImmunologyHemoglobinbusinessEPO
researchProduct